Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock
BRKR(NASDAQ:BRKR) BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced the pricing of its previously announced public offering of $600.0 million of 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker has granted the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock. The offering is expected to close on or about September 8
Bruker Announces Public Offering of $600 Million of Mandatory Convertible Preferred Stock
BRKR(NASDAQ:BRKR) BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced it has commenced a public offering, subject to market and other conditions, of $600.0 million of Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker expects to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock, solely to cover over-allotments, if any
Bruker Announces Quarterly Dividend
BRKRBILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop
Bruker Reports Second Quarter 2025 Financial Results
BRKRBILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its second quarter and for the six months ended June 30, 2025. Frank H. Laukien, Bruker’s President and CEO, commented: “Life-science research instruments demand is under pressure at the moment. Our second quarter came in below expectations, as we experienced challenging demand conditions in the US academic market, as well as in biopharma and industrial markets. Tariffs and a stiff currenc
Bruker Acquires Biocrates Life Sciences Ag, Located In Innsbruck, Austria. Financial Terms Were Not Disclosed
BRKRBruker Launches proteoElute nanoLC System, Advancing Ultra-Sensitive Proteomics
BRKRBruker Unveils New timsUltra AIP System With Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics And Metaproteomics
BRKRBruker Unveils timsMetabo Mass Spectrometer With Advanced TIMS 'MoRE' Scan-Mode
BRKRExpert Outlook: Bruker Through The Eyes Of 8 Analysts
BRKRThis Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
BRKRCitigroup Downgrades Bruker to Neutral, Lowers Price Target to $40
BRKR10x Genomics Reaches Patent Litigation Settlement With Bruker; Bruker To Pay $68M In Equal Quarterly Installments Between Q3 2025 And Q2 2026 As Well As Ongoing Royalties On Sales Of Spatial Biology Products Through Life Of Licensed Patents
BRKRBruker And 10x Genomics Settle Patent Disputes And Enter Global Cross-License Agreement, Dismissing All Ongoing Litigations
BRKRUBS Maintains Neutral on Bruker, Lowers Price Target to $45
BRKRBarclays Maintains Overweight on Bruker, Lowers Price Target to $46
BRKRGoldman Sachs Maintains Neutral on Bruker, Lowers Price Target to $45
BRKRStifel Maintains Hold on Bruker, Lowers Price Target to $48
BRKRBruker Lowers FY2025 Adj EPS Guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 Est; Raises FY2025 Sales Guidance from $3.47B-$3.54B to $3.48B-$3.55B vs $3.48B Est
BRKRBruker Q1 Adj. EPS $0.47 Beats $0.43 Estimate, Sales $801.40M Beat $764.56M Estimate
BRKRBruker Says It Will Showcase Major Spatial Biology And Multiomics Innovations At AACR 2025, Highlighting CosMx WTX And 1,200-Plex Protein Panel
BRKRA Glimpse Into The Expert Outlook On Bruker Through 6 Analysts
BRKRWells Fargo Maintains Overweight on Bruker, Lowers Price Target to $60
BRKRBruker Acquires Majority Stake In RECIPE to Advance Chrom-Free Triple-Quad Assays For Therapeutic Drug Monitoring
BRKRWhy Is Life Science Focused Bruker Stock Trading Higher On Friday?
BRKRBruker posts higher-than-expected Q1 revenue and announces NGS collaboration with Ridom to boost microbiology and infection diagnostics solutions.
Bruker Sees Q1 Revenue Between $795M And $800M, Well Ahead Of Consensus
BRKRBruker To Partner With Ridom For NGS Bioinformatics Applications In Microbiology And Infectious Disease Testing
BRKRBarclays Maintains Overweight on Bruker, Lowers Price Target to $50
BRKRCitigroup Maintains Buy on Bruker, Lowers Price Target to $50
BRKRBruker Launches 1.3 GHz High-Resolution Nuclear Magnetic Resonance System
BRKRBruker Launches Fourier 80 Multinuclear Benchtop FT-NMR Spectrometer To Enable X-Nucleus Observations And various 2D Experiments
BRKRBruker Announces Introduction Of d-DNP Polarizer For MRI Research And For Dynamic Nuclear Polarization Liquids NMR
BRKRGuggenheim Reiterates Buy on Brukerto Buy
BRKRBruker Unveils 4D-Proteomics Breakthrough At US HUPO: Enhanced Single-Cell and Immunopeptidomics With timsTOF Ultra 2 And Athena Ion Processor
BRKRStifel Maintains Hold on Bruker, Lowers Price Target to $57
BRKRBarclays Maintains Overweight on Bruker, Lowers Price Target to $60
BRKRBruker FY2025 Outlook: Adj EPS $2.67-$2.72 vs $2.67 Estimate; Sales $3.470B-$3.540B vs $3.57B Estimate
BRKRBruker Q4 2024 Adj EPS $0.76 Beats $0.74 Estimate, Sales $979.60M Beat $966.35M Estimate
BRKRBruker Expects Q4 2024 Revenue Between $970M-$980M; Projects 2025 Constant Exchange Rate Revenue Growth In Upper Mid-Single Digits
BRKRBruker Comments On Delaware District Court's Post-Trial Ruling In Case Involving GeoMx Digital Spatial Profiler Products; Says We Look Forward To The Appeal Of Our Case Being Heard By The U.S. Court Of Appeals For The Federal Circuit... We Strongly Belie
BRKRReported Earlier, Delaware Jury Awards 10x Genomics $31.7M In Patent Case Against NanoString; Permanent Injunction On GeoMx Takes Effect January 10, 2025, With Royalties For Existing Installations; Additional Rulings On CosMx Expected Spring 2025
BRKRBruker Reveals 1.2 GHz NMR Spectrometer At Swiss High-field NMR Facility
BRKRGuggenheim Initiates Coverage On Bruker with Buy Rating, Announces Price Target of $72
BRKRBruker Analysts Cut Their Forecasts After Q3 Results
BRKRCitigroup Maintains Buy on Bruker, Lowers Price Target to $75
BRKRTD Cowen Maintains Hold on Bruker, Lowers Price Target to $70
BRKRWells Fargo Maintains Overweight on Bruker, Lowers Price Target to $75
BRKRDecoding 3 Analyst Evaluations For Bruker
BRKRBarclays Maintains Overweight on Bruker, Lowers Price Target to $69
BRKRBruker shares are trading lower after the company lowered its FY24 adjusted EPS and revenue guidance.
BRKRBruker Sees FY24 Adj. EPS $2.36-$2.41 (Prior $2.59-$2.64) vs $2.59 Est., Revenues $3.34B-$3.37B (Prior $3.38B-$3.44B) vs $3.40B Est.
BRKR